174 related articles for article (PubMed ID: 35700017)
1. Proliferation of the Fallopian Tube Fimbriae and Cortical Inclusion Cysts: Effects of the Menstrual Cycle and the Levonorgestrel Intrauterine Contraceptive System.
Park KJ; Broach V; Chi DS; Linkov I; Stanczyk FZ; Patel P; Jotwani A; Pearce CL; Pike MC; Kauff ND
Cancer Epidemiol Biomarkers Prev; 2022 Sep; 31(9):1823-1829. PubMed ID: 35700017
[TBL] [Abstract][Full Text] [Related]
2. Observations on the origin of ovarian cortical inclusion cysts in women undergoing risk-reducing salpingo-oophorectomy.
Park KJ; Patel P; Linkov I; Jotwani A; Kauff N; Pike MC
Histopathology; 2018 Apr; 72(5):766-776. PubMed ID: 29197096
[TBL] [Abstract][Full Text] [Related]
3. A risk-benefit assessment of the levonorgestrel-releasing intrauterine system.
Sturridge F; Guillebaud J
Drug Saf; 1996 Dec; 15(6):430-40. PubMed ID: 8968696
[TBL] [Abstract][Full Text] [Related]
4. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding.
Lethaby A; Hussain M; Rishworth JR; Rees MC
Cochrane Database Syst Rev; 2015 Apr; (4):CD002126. PubMed ID: 25924648
[TBL] [Abstract][Full Text] [Related]
5. Impact of levonorgestrel-releasing intrauterine system use on the cancer risk of the ovary and fallopian tube.
Soini T; Hurskainen R; Grénman S; Mäenpää J; Paavonen J; Pukkala E
Acta Oncol; 2016 Nov; 55(11):1281-1284. PubMed ID: 27148621
[TBL] [Abstract][Full Text] [Related]
6. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding.
Lethaby AE; Cooke I; Rees M
Cochrane Database Syst Rev; 2005 Oct; (4):CD002126. PubMed ID: 16235297
[TBL] [Abstract][Full Text] [Related]
7. Why perimenopausal women should consider to use a levonorgestrel intrauterine system.
Wildemeersch D
Gynecol Endocrinol; 2016 Aug; 32(8):659-661. PubMed ID: 26930021
[TBL] [Abstract][Full Text] [Related]
8. A multicentre, open-label, randomised phase III study comparing a new levonorgestrel intrauterine contraceptive system (LNG-IUS 8) with combined oral contraception in young women of reproductive age.
Borgatta L; Buhling KJ; Rybowski S; Roth K; Rosen K
Eur J Contracept Reprod Health Care; 2016 Oct; 21(5):372-9. PubMed ID: 27494570
[TBL] [Abstract][Full Text] [Related]
9. Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use.
Xiao B; Zeng T; Wu S; Sun H; Xiao N
Contraception; 1995 Jun; 51(6):359-65. PubMed ID: 7554977
[TBL] [Abstract][Full Text] [Related]
10. The Effect of Age, Parity and Body Mass Index on the Efficacy, Safety, Placement and User Satisfaction Associated With Two Low-Dose Levonorgestrel Intrauterine Contraceptive Systems: Subgroup Analyses of Data From a Phase III Trial.
Gemzell-Danielsson K; Apter D; Hauck B; Schmelter T; Rybowski S; Rosen K; Nelson A
PLoS One; 2015; 10(9):e0135309. PubMed ID: 26378938
[TBL] [Abstract][Full Text] [Related]
11. The use of different doses levonorgestrel-releasing intrauterine system (LNG-IUS): real-world data from a multicenter Italian study.
Bastianelli C; Farris M; Rosato E; Varliero F; Del Savio MC; Facchinetti F; Grandi G
Eur J Contracept Reprod Health Care; 2022 Feb; 27(1):16-22. PubMed ID: 34528867
[TBL] [Abstract][Full Text] [Related]
12. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
Dominick S; Hickey M; Chin J; Su HI
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007245. PubMed ID: 26649916
[TBL] [Abstract][Full Text] [Related]
13. Levonorgestrel-releasing intrauterine system for endometrial hyperplasia.
Mittermeier T; Farrant C; Wise MR
Cochrane Database Syst Rev; 2020 Sep; 9(9):CD012658. PubMed ID: 32909630
[TBL] [Abstract][Full Text] [Related]
14. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
Chin J; Konje JC; Hickey M
Cochrane Database Syst Rev; 2009 Oct; (4):CD007245. PubMed ID: 19821400
[TBL] [Abstract][Full Text] [Related]
15. Ovarian cysts: presence and persistence with use of a 13.5mg levonorgestrel-releasing intrauterine system.
Nahum GG; Kaunitz AM; Rosen K; Schmelter T; Lynen R
Contraception; 2015 May; 91(5):412-7. PubMed ID: 25661510
[TBL] [Abstract][Full Text] [Related]
16. A randomised controlled trial of the clinical effectiveness and cost-effectiveness of the levonorgestrel-releasing intrauterine system in primary care against standard treatment for menorrhagia: the ECLIPSE trial.
Gupta JK; Daniels JP; Middleton LJ; Pattison HM; Prileszky G; Roberts TE; Sanghera S; Barton P; Gray R; Kai J;
Health Technol Assess; 2015 Oct; 19(88):i-xxv, 1-118. PubMed ID: 26507206
[TBL] [Abstract][Full Text] [Related]
17. The influence of the levonorgestrel-releasing intrauterine system position on bleeding patterns in reproductive age women.
Alves RDMS; Rabelo MM; Andrade VR; Cabral RCS; Merriman JW; Brito MB
Int J Gynaecol Obstet; 2019 Dec; 147(3):326-331. PubMed ID: 31489621
[TBL] [Abstract][Full Text] [Related]
18. Levonorgestrel-releasing intrauterine system and breast cancer risk: A systematic review and meta-analysis.
Conz L; Mota BS; Bahamondes L; Teixeira Dória M; Françoise Mauricette Derchain S; Rieira R; Sarian LO
Acta Obstet Gynecol Scand; 2020 Aug; 99(8):970-982. PubMed ID: 31990981
[TBL] [Abstract][Full Text] [Related]
19. Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of women using a levonorgestrel-releasing intrauterine system.
Critchley HO; Wang H; Kelly RW; Gebbie AE; Glasier AF
Hum Reprod; 1998 May; 13(5):1210-7. PubMed ID: 9647549
[TBL] [Abstract][Full Text] [Related]
20. Detailed analysis of menstrual bleeding patterns after postmenstrual and postabortal insertion of a copper IUD or a levonorgestrel-releasing intrauterine system.
Suvisaari J; Lähteenmäki P
Contraception; 1996 Oct; 54(4):201-8. PubMed ID: 8922872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]